The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer

项目摘要/摘要 慢性胰腺炎、糖尿病和胰腺癌(CPDPC)研究开始以来 作为一个联合体，梅奥诊所团队一直积极参与，包括领导角色，在多个 首创精神。该联盟的一个关键优先事项是促进慢性阻塞性肺疾病的机制研究 通过系统收集临床资料，研究胰腺炎、胰源性糖尿病和胰腺癌 与生物寄生虫相关的纵向队列研究中的措施。梅奥诊所团队的目标是 对最有用的纵向队列做出有意义的贡献，这将增加我们对临床的理解， 这些疾病患者的流行病学和生物学特征。主纵向 梅奥诊所将继续为之作出贡献的队列倡议(在PAR中概述)正在进行中， 点头。梅奥诊所的调查人员还将延长进行中的辅助研究(唾液生物标记物和 基于互联网的慢性胰腺炎疼痛管理技术(IMPACT))，该技术利用 广泛的基础设施已经到位。该联盟确定了三个工作组(WG)，在这些工作组中，Mayo 临床研究人员提供帮助和领导(慢性胰腺炎(CP)、3c型糖尿病 (T3cDM)；胰腺癌-DM WG。我们的贡献包括到目前为止这些研究的固定应计比率， 并成功完成了一项由非政府组织进行的辅助研究，积极参与国家行动方案队列的设计 和后续修改，以及扩展检测的应计项目。利用现有的、高效的 我们已经建立了基础设施，我们的具体目标是： 1)继续前瞻性地将Mayo患者纳入继续队列并扩大其应计金额。vbl.使用 临床研究基础设施已经到位，我们还将招募慢性胰腺炎患者和受试者 进入CPDPC内的辅助研究，其中包括：唾液生物标记物、MinimMAP和 一对。 2)继续前瞻性地登记和扩大1,322名新诊断糖尿病患者的应计项目 点头研究。 3)继续将Mayo参与者的预期应计利润引入DETECT研究。 为了实现这些目标，我们将实施和确定新的战略，以改善主要 梅奥诊所的研究以及辅助研究，同时向CPDPC提供科学、临床和 我们的调查人员的招聘经验。

PROJECT SUMMARY / ABSTRACT Since the inception of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) Consortium, the Mayo Clinic team has been an active participant, including leadership roles, in multiple initiatives. A key priority of the Consortium is the facilitation of mechanism-based research of chronic pancreatitis, pancreatogenic diabetes mellitus, and pancreatic cancer through systematically collected clinical measures in longitudinal cohort studies linked with biospecimens. The goal of the Mayo Clinic team is to contribute meaningfully to the most useful longitudinal cohorts that will increase our understanding of clinical, epidemiological, and biological characterization of patients with these conditions. The primary longitudinal cohort initiatives (outlined in the PAR) to which Mayo Clinic will continue to contribute are PROCEED and NOD. Mayo Clinic investigators will also extend ancillary studies in PROCEED (salivary biomarkers and internet based pain management techniques for pain in chronic pancreatitis (IMPACT)) that leverage the extensive infrastructure in place. The Consortium has defined three Working Groups (WG) in which Mayo Clinic investigators contribute and provide leadership (chronic pancreatitis (CP), Type 3c diabetes mellitus (T3cDM); pancreatic cancer-DM WG. Our contribution includes solid accrual rates for these studies to date, and successful completion of one ancillary study by the PI, active participation in the design of the NOD cohort and subsequent modifications, and extending accrual for DETECT. Using the existing, highly productive infrastructure we have established, our Specific Aims are to: 1) Continue to prospectively enroll and expand accrual of Mayo patients into the PROCEED cohort. Using the clinical research infrastructure in place, we will also enroll chronic pancreatitis patients and subjects into ancillary studies within the CPDPC that include, among others: salivary biomarkers, MINIMAP, and PAIR. 2) Continue to prospectively enroll and expand accrual of 1,322 newly diagnosed diabetes patients into the NOD study. 3) Continue to lead and extend prospective accrual of Mayo participants into the DETECT study. To accomplish these aims, we will implement and identify new strategies to improve recruitment into the main studies as well as ancillary studies at Mayo Clinic while providing to the CPDPC the scientific, clinical and recruitment experience of our investigators.